In two randomized double-blind studies, twice-daily GSP301 nasal spray-a fixed-dose combination of olopatadine hydrochloride and mometasone furoate-significantly improved reflective Total Nasal Symptom Score (rTNSS) versus placebo (primary endpoint; presented elsewhere). GSP301 onset of action and reflective Total Ocular Symptom Scores (rTOSS) are presented here.
STUDY DESIGN
 Two similarly designed double-blind, randomized, parallel-group studies (Study 1 [NCT02631551]; Study 2
[NCT02870205]) were conducted in patients ≥12 years of age with SAR during the Spring (Study 1) and Fall/mountain cedar (Study 2) pollen seasons  Twice daily, patients self-administered study medication and self-assessed AM and PM reflective and instantaneous nasal symptoms (nasal congestion, rhinorrhea, itchy nose, and sneezing) and ocular symptoms (itching/burning, tearing/watering, and redness of eyes) in a symptom diary  Onset of action was evaluated based on changes in self-assessed nasal symptoms at 11 timepoints after the first dose administered (visit 2) 
Endpoints
 Onset of action was evaluated based on mean change from baseline in iTNSS from 15 minutes to 4 hours (11 timepoints) after the first dose administered at the study site (visit 2) compared with placebo ( Figure 2 )  Ocular symptoms were assessed through mean change from baseline to end of treatment (visit 4) in post-dose rTOSS vs placebo  AEs were also evaluated  The primary efficacy endpoint-mean change from baseline to the end of treatment in patient-reported AM and PM 12-hour rTNSS over the 14-day treatment period-for both trials has been reported elsewhere 1, 2  Only data pertaining to GSP301 and placebo are reported here
RESULTS

Patients
 A total of 1,180 and 1,176 patients were randomized in Studies 1 and 2, respectively  At baseline, patients had moderate to severe symptoms, with mean rTNSS ranging from 10.1 to 10.3, mean iTNSS ranging from 9.2 to 9.4, and mean rTOSS ranging from 7.0 to 7.2 ( Full analysis set; Study 1: GSP301 n=299; placebo n=283; Study 2: GSP301 n=292; placebo n=291. BID, twice-daily dosing; iTNSS, instantaneous Total Nasal Symptom Score; rTNSS, reflective Total Nasal Symptom Score; rTOSS, reflective Total Ocular Symptom Score; SD, standard deviation. GSP301, olopatadine 665 μg/mometasone 25 μg BID. *P<0.05 vs placebo. BID, twice-daily dosing; CI, confidence interval; iTNSS, instantaneous Total Nasal Symptom Score; LS, least squares; min, minutes.
Efficacy
 In both studies, GSP301 significantly improved ocular symptoms (rTOSS) versus placebo (P=0.001 for both studies; Table 2)   Table 2 . LS Mean Difference in Average AM and PM rTOSS with GSP301 vs Placebo Over the 14-day Treatment Period
